SCHEMBL18526419

SCHEMBL18526419

O=CC(O)CCC1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.47
HPGD P15428 2/20 0.40
ADH1B P00325 1/20 0.38
ADH1C P00326 1/20 0.38
ADH1A P07327 1/20 0.38
ADH4 P08319 1/20 0.38
ADH7 P40394 1/20 0.38
AKR1B1 P15121 1/20 0.36
CYP1A2 P05177 1/20 0.35
METAP2 P50579 1/20 0.35
EPHX1 P07099 2/20 0.34
KMT2A Q03164 1/20 0.34
HSD11B1 P28845 1/20 0.34
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759876 0.79 METAP1 (0.43) METAP1HPGDCYP1A2METAP2EPHX1
SCHEMBL10607112 0.79 METAP1 (0.43) METAP1HPGDCYP1A2METAP2EPHX1
SCHEMBL515453 0.78 ADH1B (0.40) HPGDADH1BADH1CADH1AADH4
SCHEMBL15160393 0.77 MAPT (0.34) AKR1B1
SCHEMBL11773367 0.76 METAP1 (0.41) METAP1HPGDCYP1A2METAP2EPHX1
SCHEMBL11773374 0.76 METAP1 (0.41) METAP1HPGDCYP1A2METAP2EPHX1
SCHEMBL14104894 0.75 METAP1 (0.52) METAP1HPGDADH1BADH1CADH1A
SCHEMBL10069252 0.75 METAP1 (0.52) METAP1HPGDADH1BADH1CADH1A
SCHEMBL9668100 0.75 METAP1 (0.43) METAP1HPGDADH1BADH1CADH1A
SCHEMBL2580715 0.75 METAP1 (0.50) METAP1HPGDCYP1A2METAP2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10167303-B2 Iridium organometallic complex containing a substituted dibenzo[f,h]quinoxaline and an electronic device having an emitting layer containing the iridium complex UDC IRELAND LIMITED (IE) 2019-01-01 US disclosed
EP-2802594-B1 METAL COMPLEXES WITH DIBENZO[F,H]QUINOXALINES UDC IRELAND LTD (IE) 2017-04-19 EP disclosed
US-20170044194-A1 Metal Complexes with Dibenzo[f,h]quinoxalines UDC IRELAND LTD (IE) 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167303-B2 Iridium organometallic complex containing a substituted dibenzo[f,h]quinoxaline and an electronic device having an emitting layer containing the iridium complex NDUFS5, DDT, NDUFV2 METAP1 4221/4885HPGD 454/4885ADH1B 121/4885
US-20170044194-A1 Metal Complexes with Dibenzo[f,h]quinoxalines NDUFS2, OCIAD2, NDUFS3 METAP1 4523/4885HPGD 490/4885ADH1B 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.